Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival.
These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).
2012-03-01
Eng.
The New England journal of medicine
Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. sverstov [at] mdanderson.org
N Engl J Med. 2012 Mar;366(9):799-807
© Galenicom 1999-2013